# Tesamorelin Liver Fat: What the NAFLD Research Shows

> Tesamorelin liver fat data: net hepatic fat -2.9% in a JAMA RCT, a pooled hepatic-fat-fraction drop of -4.28%, and the liver-tissue pathway evidence — all in HIV-associated NAFLD. Every figure cited.

The hepatic-fat evidence read as a ledger — the controlled-trial figures, the liver-tissue pathway data, and the hard boundary that all of it sits inside HIV-associated fatty liver.

## The short version

This page covers what the trials found about tesamorelin liver fat. NAFLD (non-alcoholic fatty liver disease) is fat building up in the liver for reasons other than alcohol. In people with HIV who also had fatty liver, tesamorelin lowered the amount of fat in the liver and quieted some of the inflammation and scarring signals around it. The figures below are real and controlled, but they all come from HIV-associated fatty liver. Tesamorelin is not FDA-approved for NAFLD in anyone, and there is no large trial in the general fatty-liver population.

## Can tesamorelin reduce liver fat?

In studied HIV populations, yes. The JAMA randomized trial (n=50) reported a net hepatic-fat reduction of -2.9% (P=0.003) on top of a visceral-fat treatment effect of -42 cm² [3]. A 2026 meta-analysis of five randomized trials pooled a hepatic-fat-fraction reduction of MD -4.28% (P<0.001) [15].

A separate analysis found that falling FGF21 (a metabolic hormone) tracked reductions in liver fat, gamma-glutamyl transpeptidase, and the FIB-4 fibrosis index — suggesting tesamorelin reduces hepatic steatosis through pathways other than raising FGF21 [7]. These findings are specific to HIV-associated fat accumulation in the [hepatic fat in NAFLD](/liver-fat) literature.

## How does tesamorelin affect the liver in NAFLD?

In HIV patients with NAFLD treated up to 12 months, tesamorelin significantly decreased 13 circulating immune-activation proteins — including chemokines and T-cell-associated molecules — with none increased, and liver-tissue transcriptomics confirmed down-regulation of hepatic immune-activation pathways [6].

Targeted proteomics in the same setting showed reduced angiogenic, fibrogenic, and pro-inflammatory mediators: VEGFA, TGFB1, and CSF1 all fell, and the declines in VEGFA and CSF1 correlated with reductions in NAFLD activity score [8]. These pathway shifts are the mechanistic correlate of the observed hepatic-fat reduction — the liver-tissue picture behind the imaging numbers.

## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?

Investigational only in this setting. In studied HIV populations, tesamorelin reduced liver fat — the JAMA trial reported a net hepatic-fat reduction of -2.9% (P=0.003) [3], and the 2026 meta-analysis pooled a hepatic-fat-fraction drop of MD -4.28% [15]. Liver-tissue work showed down-regulation of hepatic immune-activation and fibrogenic pathways [6][8]. There is no FDA approval for NAFLD, and these findings are specific to HIV-associated fatty liver.

## Fibrosis: what the biopsy and proteomic record adds

A tesamorelin-versus-placebo trial in 61 people with HIV-associated NAFLD took serial liver biopsies. At baseline, 43% had hepatic fibrosis, and visceral fat content was higher in those with fibrosis; each 25 cm² of higher baseline visceral fat raised the odds of 12-month fibrosis progression by 37% [9]. Visceral adiposity emerged as a novel predictor of worsening fibrosis, while baseline histology did not predict progression.

Plasma proteomics from the same program found that fibrosis (stages 2-3 versus 0-1) was associated with up-regulation of 20 proteins, including matrix metalloproteinase 2, IGF-binding protein 7, and collagen alpha1(I) chain, which correlated with visceral adiposity and glucose intolerance [10]. The fibrosis story is one of tissue-repair and immune-response signatures tracking the same visceral-fat axis tesamorelin targets.

## Where the liver-fat evidence stops

Every hepatic-fat figure on this page comes from people with HIV. Tesamorelin is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy [5]; it is not approved for NAFLD or MASLD in any population. The mechanism is plausible beyond HIV, but plausibility is not a completed trial. No large general-population fatty-liver RCT has been reported, and any such use is off-label and investigational [12].

---

Tesarx files the tesamorelin record as a flat, hard-bordered data sheet — every visceral-fat and IGF-1 figure logged straight to its study, the lone HIV-lipodystrophy approval and the off-label edge ruled in plain view; an exposed-document digest, never a clinic, a pharmacy, or a prescription.